Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents

Publication Date: June 4, 2019

Key Points

Key Points

Use of erythropoiesis-stimulating agents (ESAs) to manage anemia raises hemoglobin levels and reduces the need for red blood cell transfusions but increases the risk of thromboembolic events.

ESAs are indicated in cancer patients who are receiving myelosuppressive chemotherapy with non-curative intent and anemia that cannot be adequately managed with transfusional support.

Treatment

...eatment...

...linical circumstances ESAs may be offered to pati...


...be offered to patients with chemotherapy-associa...


...be offered to most patients with n...


...red to patients with lower risk myelodysplastic s...


...myeloma, non-Hodgkin’s lymphoma, or chronic lym...


...an ESA, clinicians should conduct an appropriat...


...l considers epoetin beta and alfa, darbepoetin...


...increase the risk of thromboembolism,...


...commended that starting and modifying doses of ES...


...reased to the lowest concentration needed t...


...discontinued in patients who do not respond wi...


...ment may be used to improve hemoglobin response...


...ggested Baseline Investigations for Anem...


...ult DosingHaving trouble viewing table? Expand...


...timated Prices of ESAs and Supplemental IronH...